中国药房Issue(27)：3797-3799,3.DOI:10.6039/j.issn.1001-0408.2015.27.20
罗格列酮对比二甲双胍治疗2型糖尿病有效性和安全性的系统评价
Systematic Review of the Efficacy and Safety of Rosiglitazone and Metformin in the Treatment of Type 2 Dia-betes
摘要
Abstract
OBJECTIVE:To systematically review the efficacy and safety of rosiglitazone and metformin in the treatment of type 2 diabetes,and provide evidence-based reference for the clinical treatment. METHODS:Retrieved from PubMed,Medline, EMBase,Cochrane Library,CJFD,VIP and Wanfang database,randomized controlled trials (RCT) about rosiglitazone (test group)and metformin(control group)in the treatment of type 2 diabetes. After data extract and quality evaluation,Meta-analysis was performed by using Rev Man 5.0 statistics software. RESULTS:A total of 5 RCT were included involving 636 patients. Re-sults of Meta-analysis showed the incidence of diarrhea [RR=0.23,95%CI(0.07,0.81),P=0.000] in test groupwere significantly lower than control group,the HbA1c level [MD=0.22,95%CI(0.07,0.38),P=0.004],the incidence of edema [RR=0.20,95%CI (0.05,0.57),P=0.011] in test group was significantly higher than control group,and there was no significant difference in the fast-ing blood glucose level[MD=0.27,95%CI(-0.26,0.79),P=0.32],the incidence of nausea/vomiting [RR=0.94,95%CI(0.06, 0.89),P=0.692]between 2 groups. CONCLUSIONS:Metformin is more effective than rosiglitazone in the treatment of type 2 dia-betes,however,the incidence of diarrhea should be noticed. Due to the limit of methodological quality and sample size,it remains to be further verified with more rigorously designed and long-term follow-up of large-scale RCT.关键词
罗格列酮/二甲双胍/2型糖尿病/有效性/安全性/系统评价Key words
Rosiglitazone/Metformin/Type 2 diabetes/Efficacy/Safety/Systematic review分类
医药卫生引用本文复制引用
王鹏,杨蕊,崔学艳,李妍,李宏建,苏乐群..罗格列酮对比二甲双胍治疗2型糖尿病有效性和安全性的系统评价[J].中国药房,2015,(27):3797-3799,3.基金项目
国家科技支撑计划子课题 （）
